tility of N acetyl cysteine in preventing progression of Covid19 pneumonia.

Not Applicable

Conditions: Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Registration Number: CTRI/2021/11/038136

Lead Sponsor: Rajiv Gandhi University of Health Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: ot Yet Recruiting

Sex: Not specified

Target Recruitment: 0

Inclusion Criteria

1.Hospitalized adult age 18 to 70 years

2.Laboratory-confirmed SARS-CoV-2 infection as determined by polymerase chain reaction (PCR) or other commercial or public health assay

3.Moderate Covid-19 patients not requiring organ support

4.Mild Covid requiring hospitalization

5 Duration of Hospital less than 48 hours.

Exclusion Criteria

1. Unlikely to survive after 48 hours from screening or unlikely to remain at the investigational site beyond 48 hours

2. Requiring organ support at screening (Organ support defined as need for ICU care, mechanical ventilation, Non Invasive Ventilation (NIV), High flow Nasal Oxygen at screening

3. Participation in any other clinical trial of an experimental treatment for COVID-19

4. Known hypersensitivity to the trial drug or its components

5. Pregnant women or women who are breastfeeding

6. Consideration by the investigator, for any reason, that the subject is an unsuitable candidate to receive study treatment

7. Unable to provide consent

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1.Need for Organ Support <br/ ><br>2.All-cause Mortality at 28 days <br/ ><br> <br/ ><br>Timepoint: 1.All-cause Mortality at 28 days <br/ ><br> <br/ ><br>

Secondary Outcome Measures